Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

Authors:

Ayobami Akenroye Grace Lassiter John W Jackson Corinne Keet Jodi Segal G Caleb Alexander Hwanhee Hong

J Allergy Clin Immunol 2022 Jun 27. Epub 2022 Jun 27.

Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.

Background: The comparative safety and efficacy of the biologics currently approved for asthma are unclear.

Objective: We compared the safety and efficacy of mepolizumab, benralizumab, and dupilumab in individuals with severe eosinophilic asthma.

Methods: We performed a systematic review of peer-reviewed literature published 2000 to 2021. We studied Bayesian network meta-analyses of exacerbation rates, prebronchodilator FEV, the Asthma Control Questionnaire, and serious adverse events in individuals with eosinophilic asthma.

Results: Eight randomized clinical trials (n = 6461) were identified. We found in individuals with eosinophils ≥300 cells/μL the following: in reducing exacerbation rates compared to placebo: dupilumab (risk ratio [RR], 0.32; 95% credible interval [CI], 0.23 to 0.45), mepolizumab (RR, 0.37; 95% CI, 0.30 to 0.45), and benralizumab (RR, 0.49; 95% CI, 0.43 to 0.55); in improving FEV: dupilumab (mean difference in milliliters [MD] 230; 95% CI, 160 to 300), benralizumab (MD, 150; 95% CI, 100 to 200), and mepolizumab (MD, 150; 95% CI, 66 to 220); and in reducing Asthma Control Questionnaire scores: mepolizumab (MD, -0.63; 95% CI, -0.81 to -0.45), dupilumab (MD, -0.48; 95% CI, -0.83 to -0.14), and benralizumab (MD, -0.32; 95% CI, -0.43 to -0.21). In individuals with eosinophils 150-299 cells/μL, benralizumab (RR, 0.62; 95% CI, 0.52 to 0.73) and dupilumab (RR, 0.60; 95% CI, 0.38 to 0.95) were associated with lower exacerbation rates; and only benralizumab (MD, 81; 95% CI, 8 to 150) significantly improved FEV. These differences were minimal compared to clinically important thresholds. For serious adverse events in the overall population, mepolizumab (odds ratio, 0.67; 95% CI, 0.48 to 0.92) and benralizumab (odds ratio, 0.74; 95% CI, 0.59 to 0.93) were associated with lower odds of a serious adverse event, while dupilumab was not different from placebo (odds ratio, 1.0; 95% CI, 0.74 to 1.4).

Conclusion: There are minimal differences in the efficacy and safety of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma.

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jaci.2022.05.024	DOI Listing

June 2022

Publication Analysis

Top Keywords

95%

exacerbation rates

mepolizumab benralizumab

benralizumab dupilumab

control questionnaire

adverse events

individuals eosinophils

dupilumab eosinophilic

Keyword Occurance

Similar Publications

Efficacy of antimalarial agents to prevent the progression of discoid lupus erythematosus to systemic lupus erythematosus: A retrospective cross-sectional study.

Authors:

Thanaporn Puaratanaarunkon Stephen J Kerr Pawinee Rerknimitr

Asian Pac J Allergy Immunol 2022 Aug 22. Epub 2022 Aug 22.

Division of Dermatology, Department of Medicine, Faculty of Medicine, Skin and Allergy Research Unit, Chulalongkorn University.

Background: Discoid Lupus Erythematosus (DLE) patients have the potential to developing Systemic Lupus Erythematosus (SLE) at a later time. The prescription of antimalarial agents might be beneficial to prevent this progression but the validated data is still lacking.

Objective: Our study aimed to explore whether antimalarial agent could slow progression to SLE in DLE patients, adjusting for other potential confounders. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Stability, survival, and patient satisfaction with CAD/CAM versus conventional multistranded fixed retainers in orthodontic patients: a 6-month follow-up of a two-centre randomized controlled clinical trial.

Authors:

Arwa Gera Helen Pullisaar Paolo M Cattaneo Shadi Gera Vaska Vandevska-Radunovic Marie A Cornelis

Eur J Orthod 2022 Aug 14. Epub 2022 Aug 14.

Melbourne Dental School, Faculty of Medicine, Dentistry and Health Sciences, Melbourne, Australia.

Objectives: The primary aim of this two-arm parallel two-centre randomized controlled trial was to compare computer-aided design and computer-aided manufacturing (CAD/CAM) versus conventional multistranded fixed retainers (FRs) in terms of stability over 6 months. Secondary outcomes were failure rates and patient satisfaction.

Methods: Patients were randomized to CAD/CAM or conventional FRs in both arches, in 1:1 ratio and blocks of four. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Talking about cancer: Patient responses to raising awareness of oral cancer in primary dental care.

Authors:

Suzanne E Scott Geanina Bruj Shahryar Beheshti Ruth Evans Oluwatunmise Awojobi

Community Dent Oral Epidemiol 2022 Aug 14. Epub 2022 Aug 14.

Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK.

Objectives: Dentists and other members of the dental team could raise awareness by talking about oral cancer during routine dental check-ups. A communication guide has been developed to facilitate this. However, it has been suggested that discussions about oral cancer may raise patients' anxiety and this has been documented by dentists as a barrier to having these conversations. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Perceived experiences of racism linked to dental fear and anxiety among Black women.

Authors:

Brenda Heaton Julia C Bond Jaeyoung Bae Yvette Cozier

Community Dent Oral Epidemiol 2022 Aug 14. Epub 2022 Aug 14.

Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA.

Objectives: Dental fear and anxiety are known determinants of delaying or avoiding dental care and vary considerably based on factors such as age and gender. However, little is known about dental fear and anxiety in racial/ethnic minority populations, which bear a disproportionate burden of poor oral health outcomes. Structural and social pathways responsible for producing these disparities are also understudied. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Smart working perception in banking companies' employees during the COVID-19 pandemic: A cross-sectional pilot study.

Authors:

La Torre Giuseppe Chiappetta Marta Mazzalai Elena Gresele Riccardo Bazzo GianRomolo Pederzolli Giancarlo Azzolin Delfo Lo Izzo Antonio Mannocci Alice

Work 2022 Aug 6. Epub 2022 Aug 6.

Faculty of Economics, Universitas Mercatorum, Rome, Italy.

Background: The COVID-19 pandemic forced companies to make decisions to re-assess working-time and location in order to ensure business survival. The resorting to Smart Working (SW) has been adopted to support business continuity, especially in the banking sector.

Objective: This study aims at evaluating the attitude and opinions of the bank employees on SW, focusing on the demographic, social and occupational characteristics of the respondents. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

}

Search Our Scientific Publications & Authors